Document Detail


Efficacy and safety of topical tacrolimus for the treatment of face and neck vitiligo.
MedLine Citation:
PMID:  20175845     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Vitiligo is a common acquired idiopathic hypomelanotic disorder characterized by circumscribed depigmented maculae. The conventional treatments are limited by their inconsistent and incomplete responses, relapse rate, inconvenience to apply, side-effects and especially long-term effects. The aim of the present study was to determine the efficacy and safety of topical tacrolimus as monotherapy for the treatment of face/neck vitiligo in Taiwan. This was a multicenter, open-label, non-comparative study. Patients were at least 16 years old and had vitiligo lesions with Vitiligo Index of Disease Activity score +1 or more on face or neck. Patients received a monotherapy with 0.1% of tacrolimus ointment twice daily for 12 weeks. The efficacy was measured by the percentage of repigmentation of target lesion, which was graded as minimal (1-25%), mild (26-50%), moderate (51-75%) or excellent (76-100%). Patients who had at least mild repigmentation were defined as responders. A total of 61 patients were enrolled in this investigation. Most of the patients showed repigmentation at week 4. At the end of treatment, all patients showed repigmentation and 45.9% of patients were responders. During the study, 15 adverse events related to the ointment were reported. All the reported adverse events were mild and similar to the well-known adverse effect of tacrolimus in the treatment of atopic dermatitis. Tacrolimus ointment is effective and well tolerated for the treatment of patients with vitiligo in Taiwan. It will be another drug of choice for persons with vitiligo who are unable to receive regular phototherapy and fear the side-effects of topical steroid in long-term use.
Authors:
Yuan-Hsin Lo; Gwo-Shing Cheng; Chieh-Chen Huang; Wen-Yu Chang; Chieh-Shan Wu
Related Documents :
7208685 - Topical chemotherapy of pigment abnormalities in surgical patients.
21262575 - Intraoperative assessment of mitral valve area after mitral valve repair: comparison of...
21772985 - Early responses to intravitreal ranibizumab in typical neovascular age-related macular ...
2431015 - Permethrin 5% dermal cream: a new treatment for scabies.
23967415 - Susceptibility to hypoxia and breathing control changes after short-term cold exposures.
11442955 - Antibiotic prophylaxis for endocarditis prevention during transesophageal echocardiogra...
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study    
Journal Detail:
Title:  The Journal of dermatology     Volume:  37     ISSN:  1346-8138     ISO Abbreviation:  J. Dermatol.     Publication Date:  2010 Feb 
Date Detail:
Created Date:  2010-02-23     Completed Date:  2010-06-07     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7600545     Medline TA:  J Dermatol     Country:  England    
Other Details:
Languages:  eng     Pagination:  125-9     Citation Subset:  IM    
Affiliation:
Department of Dermatology, Shin-Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Cutaneous
Adolescent
Adult
Aged
Child
Dermatitis, Atopic / drug therapy
Face / pathology
Female
Humans
Immunosuppressive Agents / administration & dosage,  adverse effects,  therapeutic use*
Male
Middle Aged
Neck / pathology
Prospective Studies
Skin Pigmentation / drug effects*
Tacrolimus / administration & dosage,  adverse effects,  therapeutic use*
Taiwan
Vitiligo / drug therapy*
Young Adult
Chemical
Reg. No./Substance:
0/Immunosuppressive Agents; 109581-93-3/Tacrolimus

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  New algorithm (KAWAKAMI algorithm) to diagnose primary cutaneous vasculitis.
Next Document:  Relationship between the distribution of pseudoxanthoma elasticum skin and mucous membrane lesions a...